Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Multiple Myeloma 85Lymphoma, Follicular 18Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms, Plasma Cell 8Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma, Mantle-Cell 4Hematologic Diseases 4Smoldering Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Disease Progression 3Paraproteinemias 2Myelodysplastic Syndromes 2Disease 2Anemia 2Sezary Syndrome 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Limb-girdle muscular dystrophy, type 2C 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13epoetin beta 3Erythropoietin 3telapristone acetate 2luspatercept 2ferric carboxymaltose 2Lenalidomide 2Ferric Oxide, Saccharated 2Cisplatin 2Blood Transfusion 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ibrutinib 1fludarabine phosphate 1fludarabine 1ferrous sulfate 1ferric gluconate 1ferric derisomaltose 1fanasil, pyrimethamine drug combination 1Taxes 1Sugars 1Sucrose 1Solutions 1Saline Solution 1Rituximab 1Radiotherapy 1Pharmacogenomic Testing 1Paclitaxel 1Iron-Dextran Complex 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Anemia × Lenalidomide × Clear all
NCT00843882 2026-05-01

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00179621 2011-04-14

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Celgene

Phase 3 Completed
205 enrolled 25 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡